Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?

Ruaño G, Thompson PD, Kane JP, Pullinger CR, Windemuth A, Seip RL, Kocherla M, Holford TR, Wu AH.

Pharmacogenomics. 2010 Jul;11(7):959-71. doi: 10.2217/pgs.10.58.

2.
3.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
4.

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.

Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, Salisbury BA, Ginsburg GS.

Circ Cardiovasc Genet. 2008 Dec;1(2):100-6. doi: 10.1161/CIRCGENETICS.108.795013. Epub 2008 Dec 9.

5.
6.

Effect of two intensive statin regimens on progression of coronary disease.

Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.

N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.

8.

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.

McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group.

Curr Med Res Opin. 2003;19(8):689-98.

PMID:
14687438
10.

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.

Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group.

Diabetes Obes Metab. 2005 Jul;7(4):430-8. Erratum in: Diabetes Obes Metab. 2005 Jul;7(4):460.

PMID:
15955130
11.

Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?

Glueck CJ, Rawal B, Khan NA, Yeramaneni S, Goldenberg N, Wang P.

Metabolism. 2009 Feb;58(2):233-8. doi: 10.1016/j.metabol.2008.09.019.

PMID:
19154957
12.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group.

Am J Cardiol. 2003 Jul 15;92(2):152-60.

PMID:
12860216
13.

Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.

Rader DJ, Davidson MH, Caplan RJ, Pears JS.

Am J Cardiol. 2003 Mar 6;91(5A):20C-23C; discussion 23C-24C.

PMID:
12646340
14.

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group.

Am J Cardiol. 2007 Jun 1;99(11):1538-43. Epub 2007 Apr 16.

PMID:
17531577
15.

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.

Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG.

Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C.

PMID:
12646338
16.

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB.

Circ Cardiovasc Genet. 2013 Aug;6(4):400-8. doi: 10.1161/CIRCGENETICS.113.000099. Epub 2013 Jul 22.

17.

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators.

Curr Med Res Opin. 2005 Aug;21(8):1307-15.

PMID:
16083541
18.

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.

Am Heart J. 2006 May;151(5):975.e1-9.

PMID:
16644314
19.
20.

Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.

Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.

Am J Manag Care. 2006 Nov;12(15 Suppl):S412-23.

Supplemental Content

Support Center